IRIS
CAMPOCHIARO, CORRADO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 205
EU - Europa 203
NA - Nord America 122
Continente sconosciuto - Info sul continente non disponibili 1
Totale 531
Salva come PNG Salva come JPEG
Nazione #
CN - Cina 123
US - Stati Uniti d'America 119
IT - Italia 101
SG - Singapore 62
SE - Svezia 26
RU - Federazione Russa 25
DE - Germania 10
FI - Finlandia 10
KR - Corea 8
IN - India 7
NO - Norvegia 6
NL - Olanda 5
GB - Regno Unito 4
AT - Austria 3
CA - Canada 3
FR - Francia 3
LT - Lituania 3
PT - Portogallo 3
ES - Italia 2
HK - Hong Kong 2
BE - Belgio 1
EU - Europa 1
IE - Irlanda 1
PK - Pakistan 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 531
Salva come PNG Salva come JPEG
Città #
Shanghai 60
Singapore 49
Milan 27
Boardman 23
New York 19
Ashburn 13
Guangzhou 10
Moscow 10
Naples 8
Seongnam-si 8
Vaprio d'Adda 8
Oslo 6
Rome 6
Beijing 5
Dallas 5
Helsinki 5
Lappeenranta 5
Santa Clara 5
Frankfurt am Main 4
Lawrence 4
Princeton 4
Shenzhen 4
Amadora 3
Ancona 3
Bergamo 3
Cagliari 3
Osimo 3
Turin 3
Amsterdam 2
Angers 2
Barcelona 2
Foshan 2
Hyde Park 2
Hyderabad 2
Kassel 2
Marana 2
New Delhi 2
Nuremberg 2
Ottawa 2
Pune 2
Sala Baganza 2
West Jordan 2
Zhengzhou 2
Balasore 1
Brussels 1
Buffalo 1
Capaccio 1
Civitavecchia 1
Dublin 1
Fort Worth 1
Hangzhou 1
Jinhua 1
London 1
Los Angeles 1
Martina Franca 1
Newark 1
Poggiomarino 1
San Jose 1
Shijiazhuang 1
Stockton 1
Taipei 1
Taizhou 1
Tashkent 1
Toronto 1
Verdellino 1
Wuxi 1
Xi'an 1
Yekaterinburg 1
Totale 361
Salva come PNG Salva come JPEG
Nome #
Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAFV600E mutation in a patient with overlapping Erdheim-Chester/Rosai-Dorfman disease 42
La misurazione quantitativa dell’uptake di 18F-FDG in TC/PET riflette l’espansione dei plasmablasti circolanti nella malattia IgG4 correlata 31
Cardiac magnetic resonance findings in acute and post-acute COVID-19 patients with suspected myocarditis 30
Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease 28
Does the impact of COVID-19 on patients with systemic sclerosis change over time? 26
Myocarditis in anti-synthetase syndrome: clinical features and diagnostic modalities 26
Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study 25
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation 24
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review 23
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 22
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 21
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 21
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey 20
Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group 20
Clinical profiling and outcomes of viral myocarditis manifesting with ventricular arrhythmias 19
Distinctive clinical traits of lupus-related myocarditis: a multicentre retrospective study 19
Clinical Applications of FDG-PET Scan in Arrhythmic Myocarditis 18
Giant cell arteritis: Update on clinical manifestations, diagnosis, and management 17
Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of scleroderma spectrum 17
Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort 15
Multimodal Detection and Targeting of Biopsy-Proven Myocardial Inflammation in Genetic Cardiomyopathies: A Pilot Report 15
Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review 15
Cardiac involvement, a threatening very early manifestation of systemic sclerosis: evidence from VEDOSS patients 15
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 15
Case report: Successful use of mepolizumab for immune checkpoint inhibitors–induced hypereosinophilic syndrome in two patients with solid malignancies 14
Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis 14
Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study 13
Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: a EUSTAR database analysis 12
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study 11
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study 10
Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis 10
Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology 9
Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry 9
Corrigendum to “Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience” [Autoimmunity Reviews, Volume 20, Issue 12, December 2021, 102981](S1568997221002615)(10.1016/j.autrev.2021.102981) 8
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 8
Totale 642
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.494
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.494
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202 0 0 0 0 0 0 1 0 0 0 1 0
2020/20212 0 0 0 0 0 0 0 0 0 0 1 1
2021/20226 0 0 1 1 0 2 1 0 1 0 0 0
2022/202383 10 8 7 0 0 10 27 13 3 0 4 1
2023/2024277 4 10 10 25 22 37 36 35 3 18 27 50
2024/2025271 50 12 39 60 50 60 0 0 0 0 0 0
Totale 642